TREACE MEDICAL CONCEPTS INC
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
TMCI$4.78+18.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities | |||
| Net loss | $(55,743) | $(49,527) | $(42,815) |
| Adjustments to reconcile net loss to net cash used in operating activities | |||
| Depreciation and amortization expense | 8,419 | 5,352 | 2,133 |
| Provision for allowance for credit losses | 2,947 | 434 | 411 |
| Share-based compensation expense | 30,603 | 17,352 | 8,111 |
| Non-cash lease expense | 2,349 | 2,461 | 2,522 |
| Amortization of debt issuance costs | 298 | 297 | 244 |
| Gain on fair value adjustment to derivative liability | — | — | (173) |
| Debt extinguishment loss | — | — | 4,483 |
| Loss on impairment of long-lived assets | — | — | 346 |
| Amortization (accretion) of premium (discount) on marketable securities, net | (1,145) | (1,406) | (126) |
| Other, net | 538 | 205 | 25 |
| Net changes in operating assets and liabilities, net of acquisitions | |||
| Accounts receivable | (5,687) | (9,301) | (11,039) |
| Inventory | (10,010) | (9,848) | (8,769) |
| Prepaid expenses and other assets | 2,186 | (1,210) | (668) |
| Other non-current assets | (330) | — | (146) |
| Operating lease liabilities | (2,473) | (119) | 3,076 |
| Accounts payable | (1,313) | 3,167 | 4,612 |
| Accrued liabilities | (7,903) | 7,528 | 7,125 |
| Other, net | 97 | 40 | — |
| Net cash provided by (used in) operating activities | (37,167) | (34,575) | (30,648) |
| Cash flows from investing activities | |||
| Purchases of available-for-sale marketable securities | (71,579) | (169,865) | (63,409) |
| Sales and maturities of available-for-sale marketable securities | 118,547 | 120,024 | 1,729 |
| Purchases of property and equipment | (11,593) | (11,458) | (14,838) |
| Acquisition, net of cash acquired | — | (20,000) | — |
| Net cash provided by (used in) investing activities | 35,375 | (81,299) | (76,518) |
| Cash flows from financing activities | |||
| Proceeds from interest bearing term debt | — | — | 49,651 |
| Proceeds from interest bearing revolving debt | — | — | 3,850 |
| Debt issuance costs | — | — | (989) |
| Payments on interest bearing debt | — | — | (33,893) |
| Proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of $7.5 million | — | 107,527 | — |
| Proceeds from exercise of employee stock options | 428 | 1,869 | 2,187 |
| Taxes from withheld shares | (268) | (13) | — |
| Net cash provided by (used in) financing activities | 160 | 109,383 | 20,806 |
| Net increase (decrease) in cash and cash equivalents | (1,632) | (6,491) | (86,360) |
| Cash and cash equivalents at beginning of period | 12,982 | 19,473 | 105,833 |
| Cash and cash equivalents at end of period | $11,350 | $12,982 | $19,473 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest | $4,955 | $5,167 | $4,398 |
| Operating lease right-of-use assets obtained in exchange for new lease liabilities | $— | $— | $15,300 |
| Operating lease right-of-use asset and lease liability adjustment due to lease incentive | $8 | $(22) | $3,615 |
| Noncash investing activities | |||
| Unrealized (gains) losses, net on marketable securities | $66 | $(190) | $27 |
| Unsettled matured marketable security and receivable from broker | $— | $3,000 | $— |
| Noncash portion of internally developed software | $— | $(11) | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.